The Biggest Drug Pricing Reform in 14 Years
In 2026, South Korea's drug pricing system undergoes its most comprehensive reform in 14 years. The reform centers on a "dual pricing policy": premiums for innovation and rational reductions for generics.
This change presents both crisis and opportunity for small pharmaceutical companies. For companies heavily dependent on generics, it's a survival issue; for those with innovation capabilities, it's a chance to leap forward.
3 Core Changes in Drug Pricing
1. Generic Drug Price Cuts
Previous first generic price: 53.55% of originalAfter reform: Reduced to 45% (~16% decrease)From H2 2026: Additional 5%p reduction when the 11th generic of same formulation is listedImpact: Direct hit on revenue for generic-dependent companies2. Expanded Innovation Drug Rewards
Innovative pharmaceutical companies: 60% price premium, guaranteed up to 4 yearsSemi-innovative category created: 50% premium, up to 4 yearsRisk-sharing agreements expanded to all innovative drugsFast-track listing: Target 240 days → within 100 days3. Biosimilar Pricing Reform
Dedicated biosimilar pricing framework establishedBiosimilars included in drug price refund systemPermit process reform targeting world's fastest market launchImpact on Small Pharmaceutical Companies
Risk Factors
Revenue decline: Companies with 80%+ generic dependence expect 10~20% annual revenue dropMargin compression: Selling price drops against fixed costsRestructuring pressure: Inevitable pruning of uncompetitive generic productsReduced investment capacity: Concerns about shrinking R&D budgetsOpportunity Factors
Innovation drug incentives: 50% price premium for semi-innovative designationNiche market opportunities: Expanded rewards for rare diseases and essential medicinesBiosimilar entry: Higher margins compared to chemical genericsExpanded government R&D support: New 150 billion KRW Phase 3 specialized fund5 Strategies for Innovation Transition
Strategy 1: Start with Modified New Drugs (505(b)(2))
Incremental innovation leveraging existing generic capabilitiesDevelop modified new drugs through formulation changes, combinations, extended releaseReduced clinical trial scale compared to NCEs, shorter development timelinesAccess to price premiums + market exclusivityStrategy 2: Focus on Niche Markets
Rare diseases: Small patient populations but premium pricing possibleEssential medicines: Expanded price protection with supply obligationsOrphan drugs: Stable revenue with regulatory incentivesStrategy 3: Build Biosimilar Pipeline
Invest in transition from chemical synthesis to bio capabilitiesReduce initial investment through CDMO partnerships2026 CDMO Special Act implementation lowers entry barriersStrategy 4: Acquire AI Drug Discovery Capabilities
Utilize AI-based target discovery and lead optimization platformsPursue joint research with AI biotechs rather than in-house developmentImproved clinical efficiency can reduce development costs by 30~50%Strategy 5: Pursue Semi-Innovative Company Designation
Maintain R&D investment ratio above 7% of revenueSecure minimum 2 clinical pipelinesBuild patent filing and technology transfer track recordsGovernment Support Programs
| Program | Support | Target |
|---------|---------|--------|
| Phase 3 Specialized Fund | 150B KRW investment | Bio companies entering Phase 3 |
| K-Bio & Vaccine Fund | 1T KRW (through 2027) | Broad bio sector |
| TIPS Bio | Up to 800M KRW R&D | Bio startups |
| Innovation Voucher | Technology & consulting | Small pharma companies |
KITIM Bio Consulting
KITIM provides specialized consulting for SME pharma and biotech companies' innovation transitions.
Innovation transition roadmap: Step-by-step plan from generics to innovative drugsGovernment support matching: Bio R&D program discovery and proposal writingRegulatory strategy: R&D portfolio advisory for meeting price premium requirements